Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related deaths
worldwide. HCC initiation, progression, and therapy failure are all influenced by various …

Sorafenib (Nexavar®) is currently the only systemic agent approved for use in hepatocellular
carcinoma (HCC). Its approval was based on the results of the pivotal SHARP and Sorafenib …

Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide and the
second most lethal human cancer. A portion of patients with advanced HCC can significantly …

Antiangiogenic and cytotoxic effects are considered the principal mechanisms of action of
sorafenib, a multitarget kinase inhibitor approved for the treatment of hepatocellular …

The poor outcome of patients with non-surgically removable advanced hepatocellular
carcinoma (HCC), the most frequent type of primary liver cancer, is mainly due to the high …

Sorafenib is a multi-kinase inhibitor and one of the few systemic treatment options for
patients with advanced hepatocellular carcinomas (HCCs). Resistance to sorafenib …

Simple Summary Hepatocellular carcinoma (HCC) is characterized by a broad molecular
and genetic heterogeneity, which makes it a challenging subject in terms of the underlying …

Ferroptosis is a promising therapeutic approach for combating malignant cancers, but its
effectiveness is limited in clinical due to the adaptability and self-repair abilities of cancer …

In recent years, circular RNAs (circRNAs) have been shown to have critical regulatory roles
in the resistance to anti-cancer drugs. However, the contributions of circRNAs to sorafenib …

Herein, both strategies of synergistic drug combination together with dual active tumor
targeting were combined for effective therapy of hepatocellular carcinoma (HCC). Therefore …